CACHE Challenge #1: targeting the WDR domain of LRRK2, a Parkinson's Disease associated protein.
Fengling LiiD, Suzanne Z. AcklooiD, C. H. ArrowsmithiD, Fuqiang BaniD, Christopher BardeniD, Hartmut BeckiD, Jan BeránekiD, Francois BerengeriD, Albina Bolotokova, Guillaume BretiD, Marko BreznikiD, Emanuele CarosatiiD, Irene ChauiD, Yu CheniD, Artem R CherkasoviD, Dennis Della CorteiD, Katrin DenzingeriD, Aiping DongiD, Sorin DragaiD, Ian C. DunniD, Kristina EdfeldtiD, A.M. EdwardsiD, Merveille EguidaiD, Paul EisenhuthiD, Lukas FriedrichiD, , Matthieu SchapiraiD
Abstract
The CACHE challenges are a series of prospective benchmarking exercises meant to evaluate progress in the field of computational hit-finding. Here we report the results of the inaugural CACHE #1 challenge in which 23 computational teams each selected up to 100 commercially available compounds that they predicted would bind to the WDR domain of the Parkinsons disease target LRRK2, a domain with no known ligand and only an apo structure in the PDB. The lack of known binding data and presumably low druggability of the target is a challenge to computational hit finding methods. Seventy-three of the 1955 procured molecules bound LRRK2 in an SPR assay with KD lower than 150 M and were advanced to a hit expansion phase where computational teams each selected up to 50 analogs each. Binding was observed in two orthogonal assays with affinities ranging from 18 to 140 M for seven chemically diverse series. The seven successful computational workflows varied in their screening strategies and techniques. Three used molecular dynamics to produce a conformational ensemble of the targeted site, three included a fragment docking step, three implemented a generative design strategy and five used one or more deep learning steps. CACHE #1 reflects a highly exploratory phase in computational drug design where participants sometimes adopted strikingly diverging screening strategies. Machine-learning accelerated methods achieved similar results to brute force (e.g. exhaustive) docking. First-in-class, experimentally confirmed compounds were rare and weakly potent, indicating that recent advances are not sufficient to effectively address challenging targets.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 34
- FWCI
- 4.54
- Field percentile
- top 4%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development of LRRK2 designed ankyrin-repeat proteins
V. Dederer, M. Sanz Murillo, … S. Knapp·bioRxiv·Nov 14, 2023
- A resource to enable chemical biology and drug discovery of WDR Proteins
Suzanne Z. Ackloo, Fengling Li, … C. H. Arrowsmith·Journal of Medicinal ChemistryPeer-reviewed·Nov 4, 2024
- Benchmarking ensemble docking methods as a scientific outreach project
- Protein Domain-Based Prediction of Compound-Target Interactions and Experimental Validation on LIM Kinases
Tunca Doğan, Ece Akhan Güzelcan, … Rengül Çetin-Atalay·PLoS Computational BiologyPeer-reviewed·Nov 29, 2021
- Identification of putative druggable pockets in PRL3, a significant oncology target, using in silico analysis
G. M. Bennett, J. Starczewski, M. V. C. dela Cerna·bioRxiv·Jul 31, 2023
- Discovery of BAZ2A Bromodomain Ligands
D. Spiliotopoulos, E.-C. Wamhoff, … A. Caflisch·bioRxiv·Jun 7, 2017